PHRT has established two platforms in Switzerland for large clinical sample cohorts, that generate consistent, high quality genomic, transcriptomic and proteomic data. Each platform has the capacity to process several thousand samples per year. Both platforms offer processing of primary digital data collected from the samples to the stage of quantitative profiles. Both platforms have been extensively bench-marked and are operational.
The CGAC, based in Geneva, aims to provide forthe large-scale sequencing needsof Switzerland, thereby facilitating genomic research and the implementation of genomic-based medicine.
The CPAC in Zurich is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of disease/wellness, through the development and application of robust,quantitative,mass spectrometry-based strategies.
The CMAC provides untargeted and high-throughput methods for the unbiased analysis of human samples. It is ideally suited for biomarker discovery in large cohorts, and ideally complements genomics and proteomics analyses with a functional readout. The Center is located in Zurich, and cooperates tightly with the Proteomics platform to provide a one-stop shop for clinical mass spectrometry.
Through “Pioneer Imaging Projects” (PIP), PHRT explores strategies, approaches, methods and options for a new Clinical Imaging Hub in the ETH Domain. During the second PHRT phase, these PIPs shall transform into a multi-centric Clinical Imaging Hub that will sustain after PHRT comes to its end in 2024.